HER2-HSV

HER2-HSV (including recombinants such as R-LM113 and R-LM249) is a non-attenuated, fully retargeted oncolytic herpes simplex virus (oHSV) engineered to selectively target and destroy HER2-positive cancer cells. Developed by researchers at the University of Bologna, the virus is genetically modified by replacing key glycoprotein D (gD) sequences with a single-chain variable fragment (scFv) antibody derived from trastuzumab. This modification detargets the virus from its natural receptors, HVEM and nectin-1, while restricting its entry and replication exclusively to cells overexpressing human epidermal growth factor receptor 2 (HER2). In preclinical models, HER2-HSV has demonstrated significant therapeutic efficacy against disseminated HER2-positive carcinomas, including breast cancer, ovarian cancer, and glioblastoma, both through direct oncolysis and by stimulating a systemic antitumor immune response.

Other names

HER-2-retargeted oncolytic herpes virusHER2-retargeted oncolytic herpes virusHER 2-retargeted oncolytic herpes virusHER2-ReHVHER-2-ReHVHER 2-ReHVHER2-retargeted oncolytic herpes simplex virusHER-2-retargeted oncolytic herpes simplex virusHER 2-retargeted oncolytic herpes simplex virus